Inomagen Therapeutics is developing a revolutionary gene therapy to improve the treatment of atrial fibrillation, a condition afflicting 37 million people worldwide; Submits Phase 1 Segment interim results to NIH; Phase 1 completion planned by the end of this year.
Rhythm Therapeutics, Inc. Awarded $3.67 million NIH SBIR Fast Track Grant to Develop Gene Therapy for Atrial Fibrillation
Share Article
Chicago-based Rhythm Therapeutics is led by founder Dr. Rishi Arora, Professor of Medicine, Clinical Cardiac Electrophysiology at Northwestern University - The Feinberg School of Medicine; Grant is from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, and from the Small Business Innovation Research program that can total up to $3.67 million; Atrial fibrillation is the most common heart rhythm disorder, affecting six million people in the U.S. and 33 million worldwide.
Rishi Arora, MD, FHRS, FAHA